Bryleos

About:

Bryleos is a clinical-stage therapeutics company.

Top Investors: Eddie Jordan

Description:

Bryleos is a clinical-stage therapeutics company. It uses the strength of a systems approach to directly address the burden of expensive chronic illnesses. Bryleos has created an oral formulation of NAD+ that is patent-pending and has the ability to support each cell's optimal function using cutting-edge technology.

Total Funding Amount:

$5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Johnson City, Tennessee, United States

Founded Date:

2021-01-01

Contact Email:

info(AT)bryleos.com.

Founders:

Wendy Komac

Number of Employees:

1-10

Last Funding Date:

2023-06-13

IPO Status:

Private

Industries: